Comparison of pTau217 and Tau PET between Down syndrome and neurotypical adults at risk for Alzheimer’s disease

Abstract

Background: Characterizing the timing and progression of Alzheimer’s disease (AD) biomarker positivity in Down syndrome (DS) and contrasting potential timing differences with neurotypical (NT) adults is needed to identify optimal anti‐amyloid treatment windows in DS.